0001193125-23-252467.txt : 20231006 0001193125-23-252467.hdr.sgml : 20231006 20231006173059 ACCESSION NUMBER: 0001193125-23-252467 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231006 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231006 DATE AS OF CHANGE: 20231006 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Talaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001827506 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40384 FILM NUMBER: 231315012 BUSINESS ADDRESS: STREET 1: 570 PRESTON ST. STREET 2: SUITE 400 CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 502-398-9250 MAIL ADDRESS: STREET 1: 93 WORCESTER STREET CITY: WELLESLEY STATE: MA ZIP: 02481 8-K 1 d509754d8k.htm 8-K 8-K
false 0001827506 0001827506 2023-10-06 2023-10-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 6, 2023

 

 

TALARIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40384   83-2377352

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

93 Worcester St.

Wellesley, Massachusetts

   02481
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (502) 398-9250

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value   TALS   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01

Regulation FD Disclosure

As previously announced, on June 22, 2023, Talaris Therapeutics, Inc., a Delaware corporation (“Talaris”), Terrain Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Talaris (“Merger Sub”), and Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Tourmaline, with Tourmaline continuing as a wholly owned subsidiary of Talaris and the surviving corporation of the merger (the “Merger”).

On October 6, 2023, Talaris issued a press release announcing that its Board of Directors has declared a special cash dividend to its stockholders in connection with the Merger (the “Special Dividend”). The Special Dividend, which Talaris estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the Special Dividend will be calculated after deducting certain cash amounts as set forth in the Merger Agreement. The ex-dividend date in respect of the Special Dividend will be before market open on October 20, 2023. As such, only the stockholders of record as of October 16, 2023, record date for the Special Dividend, that continue to hold their eligible shares of Talaris until market open on October 20, 2023 will be entitled to the dividend payment. The Special Dividend will not exceed an amount equal to $67.5 million, net of the Aggregate Cash Amount (as defined in the Merger Agreement). Payment of the Special Dividend is conditioned upon the closing of the Merger, which remains subject to the approval of Talaris’ stockholders and other closing conditions. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

This Current Report on Form 8-K and the exhibit furnished herewith contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed Merger; the anticipated timing of the closing of the Merger; the estimated price and anticipated payment date of the special dividend; and other statements that are not historical fact. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting Talaris, Tourmaline or the proposed transaction will be those that have been anticipated.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Talaris’ control. Talaris’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) the risk that the conditions to the closing of the proposed Merger are not satisfied, including the failure to timely obtain shareholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Talaris and Tourmaline to consummate the proposed Merger; (iii) risks related to Talaris’ ability to manage its operating expenses and its expenses associated with the proposed Merger pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) the risk that as a result of adjustments to the exchange ratio, Talaris shareholders and Tourmaline stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Talaris’ common stock relative to the value suggested by the exchange ratio; (vii) unexpected costs, charges or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; (ix) the uncertainties associated with Tourmaline’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (x) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (xi) uncertainties in obtaining successful clinical results for product candidates of the combined company and unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed by the combined company in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (xiii) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; (xiv) risks associated with Talaris’ financial close process; (xv) the risk that the pre-closing financing is

 

2

not consummated; and (xvi) the risk that Talaris shareholders receive more or less of the cash dividend than is currently anticipated, among others. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Talaris’ Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC, and in other filings that Talaris makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement described below under “Additional Information and Where to Find It.” You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Talaris expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. This Current Report on Form 8-K does not purport to summarize all of the conditions, risks and other attributes of an investment in Talaris or Tourmaline.

Participants in the Solicitation

This Current Report on Form 8-K and the exhibit filed or furnished herewith relate to the proposed merger transaction involving Talaris and Tourmaline and may be deemed to be solicitation material in respect of the proposed merger transaction. In connection with the proposed merger transaction, Talaris has filed relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that contains a proxy statement (the “Proxy Statement”) and prospectus. This Current Report on Form 8-K is not a substitute for the Form S-4, the Proxy Statement or for any other document that Talaris may file with the SEC and or send to Talaris’ shareholders in connection with the proposed merger transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF TALARIS ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TALARIS, THE PROPOSED MERGER TRANSACTION AND RELATED MATTERS.

No Offer or Solicitation

This Current Report on Form 8-K and the exhibit furnished herewith do not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

Investors and security holders may obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Talaris with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed by Talaris with the SEC are also available free of charge on Talaris’ website at www.talaristx.com, or by contacting Talaris’ Investor Relations at investors@talaristx.com. Talaris, Tourmaline, and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from Talaris’ shareholders with respect to the proposed merger transaction under the rules of the SEC. Information about the directors and executive officers of Talaris is set forth in its Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 31, 2023, and in subsequent documents filed with the SEC. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are also included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of this document as described above.

 

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
No.		    Description
99.1    Press Release, issued on October 6, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TALARIS THERAPEUTICS, INC.
By:  

/s/ Mary Kay Fenton

Name:   Mary Kay Fenton
Title:   Chief Financial Officer and Interim Chief Executive Officer and President

Date: October 6, 2023

 

4

EX-99.1 2 d509754dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Talaris Therapeutics Declares Special Dividend

In Connection with Proposed Merger with Tourmaline Bio

Special dividend estimated to be $1.5118 per share

Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval

BOSTON – October 6, 2023 –Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “Company”) today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the “Merger”) with Tourmaline Bio, Inc. (“Tourmaline”) pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the “Merger Agreement”).

The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the special dividend will be calculated after deducting certain cash amounts as set forth in the Merger Agreement. The ex-dividend date in respect of such special cash dividend will be before market open on October 20, 2023. As such, only the stockholders of record as of October 16, 2023, record date for the Special Dividend, that continue to hold their eligible shares of Talaris until market open on October 20, 2023 will be entitled to the dividend payment. The Special Dividend will not exceed an amount equal to $67.5 million, net of the Aggregate Cash Amount (as defined in the Merger Agreement).

Payment of the special dividend is conditioned upon the closing of the Merger with Tourmaline, which remains subject to the approval of Talaris’ stockholders and other closing conditions. The special meeting of Talaris’ stockholders to consider and vote upon the Merger is scheduled for October 17, 2023 with closing expected to occur after market close on October 19, 2023, assuming the transaction is approved by the Talaris stockholders and the satisfaction or waiver of all conditions under the Merger Agreement.

Every stockholder’s vote is important, regardless of the number of shares held. Accordingly, Talaris requests that each stockholder of record as of September 7, 2023, complete, sign, date and return a proxy card (online or by mail) as soon as possible to ensure that the stockholder’s shares will be represented at the special meeting. Stockholders who hold shares in “street name” (i.e., those stockholders whose shares are held of record by a broker, bank or other nominee) should contact their broker, bank or nominee to ensure that their shares are voted.

If any Talaris stockholder did not receive the proxy statement, such stockholder should (i) confirm his or her proxy statement’s status with his or her broker or (ii) contact Mediant Communications Inc. at engage@mediant.com or (888) 656-7251.

About Tourmaline Bio, Inc.

Tourmaline Bio is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Tourmaline’s lead program, TOUR006, is an anti-IL-6 antibody which exhibits differentiated properties including high binding affinity to IL-6 and a naturally long half-life. To date, TOUR006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline plans to develop TOUR006 in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its lead and secondary indications, respectively, with additional indications under consideration.

About Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc., prior to its review of strategic alternatives, was a cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation (“allo-HSCT”), called Facilitated Allo-HSCT Therapy.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed Merger; the anticipated timing of the closing of the Merger; the estimated price and anticipated payment date of the special dividend; and other statements that are not

historical fact. All statements other than statements of historical fact contained in this press release are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting Talaris, Tourmaline or the proposed transaction will be those that have been anticipated.

Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Talaris’ control. Talaris’ actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to (i) the risk that the conditions to the closing of the proposed Merger are not satisfied, including the failure to timely obtain shareholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each of Talaris and Tourmaline to consummate the proposed Merger; (iii) risks related to Talaris’ ability to manage its operating expenses and its expenses associated with the proposed Merger pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) the risk that as a result of adjustments to the exchange ratio, Talaris shareholders and Tourmaline stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Talaris’ common stock relative to the value suggested by the exchange ratio; (vii) unexpected costs, charges or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; (ix) the uncertainties associated with Tourmaline’s platform technologies, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion of clinical trials; (x) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (xi) uncertainties in obtaining successful clinical results for product candidates of the combined company and unexpected costs that may result therefrom; (xii) risks related to the failure to realize any value from product candidates and preclinical programs being developed and anticipated to be developed by the combined company in light of inherent risks and difficulties involved in successfully bringing product candidates to market; (xiii) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; (xiv) risks associated with Talaris’ financial close process; (xv) the risk that the pre-closing financing is not consummated; and (xvi) the risk that Talaris shareholders receive more or less of the cash dividend than is currently anticipated, among others. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Talaris’ Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC, and in other filings that Talaris makes and will make with the SEC in connection with the proposed Merger, including the Proxy Statement described below under “Additional Information and Where to Find It.” You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Talaris expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. This press release does not purport to summarize all of the conditions, risks and other attributes of an investment in Talaris or Tourmaline.

Participants in the Solicitation

This press release relates to the proposed merger transaction involving Talaris and Tourmaline and may be deemed to be solicitation material in respect of the proposed merger transaction. In connection with the proposed merger transaction, Talaris has filed relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that contains a proxy statement (the “Proxy Statement”) and prospectus. This press release is not a substitute for the Form S-4, the Proxy Statement or for any other document that Talaris may file with the SEC and or send to Talaris’ shareholders in connection with the proposed merger transaction. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF TALARIS ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TALARIS, THE PROPOSED MERGER TRANSACTION AND RELATED MATTERS.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It

Investors and security holders may obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Talaris with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed by Talaris with the SEC are also available free of charge on Talaris’ website at www.talaristx.com, or by contacting Talaris’ Investor Relations at investors@talaristx.com. Talaris, Tourmaline, and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from Talaris’ shareholders with respect to the proposed merger transaction under the rules of the SEC. Information about the directors and executive officers of Talaris is set forth in its Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the SEC on March 31, 2023, and in subsequent documents filed with the SEC. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are also included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of this document as described above.

For Talaris:

Investor Contact

Chris Brinzey

ICR Westwicke

chris.brinzey@westwicke.com

(339) 970-2843

For Tourmaline:

Lee M. Stern

Meru Advisors

lstern@meruadvisors.com

EX-101.SCH 3 tals-20231006.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tals-20231006_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 tals-20231006_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Oct. 06, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001827506
Document Type 8-K
Document Period End Date Oct. 06, 2023
Entity Registrant Name TALARIS THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40384
Entity Tax Identification Number 83-2377352
Entity Address, Address Line One 93 Worcester St.
Entity Address, City or Town Wellesley
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02481
City Area Code (502)
Local Phone Number 398-9250
Written Communications true
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol TALS
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 7 d509754d8k_htm.xml IDEA: XBRL DOCUMENT 0001827506 2023-10-06 2023-10-06 false 0001827506 8-K 2023-10-06 TALARIS THERAPEUTICS, INC. DE 001-40384 83-2377352 93 Worcester St. Wellesley MA 02481 (502) 398-9250 true false false false Common Stock, $0.0001 par value TALS NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #=BT9799!YDAD! #/ M P $P @ '&$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 "0 ) #X" 0% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d509754d8k.htm tals-20231006.xsd tals-20231006_lab.xml tals-20231006_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d509754d8k.htm": { "nsprefix": "tals", "nsuri": "http://talaristx.com/20231006", "dts": { "inline": { "local": [ "d509754d8k.htm" ] }, "schema": { "local": [ "tals-20231006.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "tals-20231006_lab.xml" ] }, "presentationLink": { "local": [ "tals-20231006_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "report": { "R1": { "role": "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-10-06_to_2023-10-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d509754d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-10-06_to_2023-10-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d509754d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://talaristx.com//20231006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001193125-23-252467-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-252467-xbrl.zip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end